Figure 2.
Coadministration of panitumumab (Pmab) and TAS‐102 induces tumor regression in vivo. Antitumor effects of Pmab, TAS‐102, and Pmab/TAS‐102 combination on the growth of subcutaneous LIM1215 (A) and COL‐01‐JCK (B) tumor xenografts. The mice were orally administered Pmab (3 mg·kg−1, twice weekly; intraperitoneally), TAS‐102 (75 mg·kg−1, twice daily on a 5‐days‐on/2‐days‐off schedule; orally), or a combination of both agents for 2 weeks (from days 1 to 14). The data represent the mean tumor volume ± standard error of the mean (n = 5).